Synergistic apoptotic effects of taurolidine and TRAIL on squamous carcinoma cells of the esophagus

International Journal of Oncology

Volumn 32, Issue 6, 2008, Pages 1205-1220

  Daigeler, Adrien ^a,b   Chromik, Ansgar Michael ^a   Geisler, Anne ^a   Bulut, Daniel ^a   Hilgert, Christoph ^a   Krieg, Andreas ^c   Klein Hitpass, Ludger ^d   Lehnhardt, Marcus ^b   Uhl, Waldemar ^a   Mittelkötter, Ulrich ^a  

^a ST JOSEF HOSPITAL   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

^c HEINRICH HEINE UNIVERSITY   (Germany)

^d UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

Apoptosis; Esophagus carcinoma; NFKB; Taurolidine; Tauroline; TRAIL

Indexed keywords

APOPTOTIC PROTEASE ACTIVATING FACTOR 1; CASPASE 3; CASPASE 8; CASPASE 9; CELL PROTEIN; CYTOCHROME C; DEATH RECEPTOR 3; FAS ASSOCIATED DEATH DOMAIN PROTEIN; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45A; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN IA; INTERLEUKIN 1BETA CONVERTING ENZYME; JANUS KINASE 2; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; PROTEIN BCL 2; PROTEIN BCL 211; PROTEIN BIRC3; PROTEIN DFFA; PROTEIN JUN; PROTEIN TNFAIP3; PROTEIN TNFRSF1A; PROTEIN TNFRSF1B; PROTEIN TNFRSF21; RECOMBINANT PROTEIN; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TAUROLIDINE; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED DEATH DOMAIN PROTEIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; TAURINE; THIADIAZINE DERIVATIVE; TUMOR MARKER; TUMOR PROTEIN;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL DEATH; CELL VIABILITY; COMBINATION CHEMOTHERAPY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENTIATION; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; MITOCHONDRIAL RESPIRATION; MONOTHERAPY; NICK END LABELING; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA ANALYSIS; SIGNAL TRANSDUCTION; DOSE RESPONSE; DRUG EFFECT; ESOPHAGUS TUMOR; METABOLISM; PATHOLOGY; SQUAMOUS CELL CARCINOMA; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; ESOPHAGEAL NEOPLASMS; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; HUMANS; IN SITU NICK-END LABELING; NEOPLASM PROTEINS; TAURINE; THIADIAZINES; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR MARKERS, BIOLOGICAL;

EID: 48149110373     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo_32_6_1205     Document Type: Article

References (89)

1. Schlag PM: Randomized trial of preoperative chemotherapy for squamous cell cancer of the esophagus. The Chirurgische Arbeitsgemeinschaft Fuer Onkologie der Deutschen Gesellschaft Fuer Chirurgie Study Group. Arch Surg 127: 1446-1450, 1992.
2. Urba SG, Orringer MB, Turrisi A, Iannettoni M, Forastiere A and Strawderman M: Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol 19: 305-313, 2001.
3. Malthaner RA, Wong RK, Rumble RB and Zuraw L: Neoadjuvant or adjuvant therapy for resectable esophageal cancer: a systematic review and meta-analysis. BMC Med 2: 35, 2004.
4. Bosset JF, Gignoux M, Triboulet JP, et al: Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med 337: 161-167, 1997.
5. Xiao ZF, Yang ZY, Liang J, Miao YJ, Wang M, Yin WB, Gu XZ, Zhang DC, Zhang RG and Wang LJ: Value of radiotherapy after radical surgery for esophageal carcinoma: a report of 495 patients. Ann Thorac Surg 75: 161-167, 2003.
6. Ancona E, Ruol A, Santi S, Merigliano S, Sileni VC, Koussis H, Zaninotto G, Bonavina L and Peracchia A: Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long-term survival of patients with resectable esophageal squamous cell carcinoma: final report of a randomized, controlled trial of preoperative chemotherapy versus surgery alone. Cancer 91: 2165-2174, 2001.
7. Kelsen DP, Minsky B, Smith M, Beitler J, Niedzwiecki D, Chapman D, Bains M, Burt M, Heelan R and Hilaris B: Preoperative therapy for esophageal cancer: a randomized comparison of chemotherapy versus radiation therapy. J Clin Oncol 8: 1352-1361, 1990.
8. Enzinger PC and Mayer RJ: Esophageal cancer. N Engl J Med 349: 2241-2252, 2003.
9. Forastiere AA: Treatment of locoregional esophageal cancer. Semin Oncol 19: 57-63, 1992.
10. Muller JM, Erasmi H, Stelzner M, Zieren U and Pichlmaier H: Surgical therapy of oesophageal carcinoma. Br J Surg 77: 845-857, 1990.
11. Badwe RA, Sharma V, Bhansali MS, Dinshaw KA, Patil PK, Dalvi N, Rayabhattanavar SG and Desai PB: The quality of swallowing for patients with operable esophageal carcinoma: a randomized trial comparing surgery with radiotherapy. Cancer 85: 763-768, 1999.
12. Geissler M, Schwacha H, Eggstein S, Usadel H, Harder J, Opitz O, Arnold C, Grimm CF and Blum HE: Esophageal carcinoma: non-surgical therapy. Schweiz Rundsch Med Prax 93: 2057-2064, 2004.
13. Kitamura K, Kuwano H, Watanabe M, Nozoe T, Yasuda M, Sumiyoshi K, Saku M and Sugimachi K: Prospective randomized study of hyperthermia combined with chemoradiotherapy for esophageal carcinoma. J Surg Oncol 60: 55-58, 1995.
14. Coia LR, Engstrom PF, Paul AR, Stafford PM and Hanks GE: Long-term results of infusional 5-FU, mitomycin-C and radiation as primary management of esophageal carcinoma. Int J Radiat Oncol Biol Phys 20: 29-36, 1991.
15. Nishimura Y, Suzuki M, Nakamatsu K, Kanamori S, Yagyu Y and Shigeoka H: Prospective trial of concurrent chemoradiotherapy with protracted infusion of 5-fluorouracil and cisplatin for T4 esophageal cancer with or without fistula. Int J Radiat Oncol Biol Phys 53: 134-139, 2002.
16. Ishida K, Ando N, Yamamoto S, Ide H and Shinoda M: Phase II study of cisplatin and 5-fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG)/Japan Clinical Oncology Group trial (JCOG9516). Jpn J Clin Oncol 34: 615-619, 2004.
17. Herskovic A, Martz K, Al-Sarraf M, Leichman L, Brindle J, Vaitkevicius V, Cooper J, Byhardt R, Davis L and Emami B: Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 326: 1593-1598, 1992.
18. Kaneko K, Ito H, Konishi K, et al: Definitive chemoradiotherapy for patients with malignant stricture due to T3 or T4 squamous cell carcinoma of the oesophagus. Br J Cancer 88: 18-24, 2003.
19. Rowinsky EK: Targeted induction of apoptosis in cancer management: the emerging role of tumor necrosis factor-related apoptosis-inducing ligand receptor activating agents. J Clin Oncol 23: 9394-9407, 2005.
20. Ashkenazi A, Pai RC, Fong S, et al: Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 104: 155-162, 1999.
21. Bouralexis S, Findlay DM and Evdokiou A: Death to the bad guys: targeting cancer via Apo2L/TRAIL. Apoptosis 10: 35-51, 2005.
22. Fesik SW: Promoting apoptosis as a strategy for cancer drug discovery. Nat Rev Cancer 5: 876-885, 2005.
23. LeBlanc HN and Ashkenazi A: Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ 10: 66-75, 2003.
24. Walczak H, Miller RE, Ariail K, et al: Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 5: 157-163, 1999.
25. Wiley SR, Schooley K, Smolak PJ, et al: Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3: 673-682, 1995.
26. Bradbury J: TRAIL leads to apoptosis in acute promyelocytic leukaemia. Lancet 357: 1770, 2001.
27. Cretney E, McQualter JL, Kayagaki N, Yagita H, Bernard CC, Grewal IS, Ashkenazi A and Smyth MJ: TNF-related apoptosis-inducing ligand (TRAIL)/ Apo2L suppresses experimental autoimmune encephalomyelitis in mice. Immunol Cell Biol 83: 511-519, 2005.
28. Yagita H, Takeda K, Hayakawa Y, Smyth MJ and Okumura K: TRAIL and its receptors as targets for cancer therapy. Cancer Sci 95: 777-783, 2004.
29. Pan G, Ni J, Yu G, Wei YF and Dixit VM: TRUNDD, a new member of the TRAIL receptor family that antagonizes TRAIL signalling. FEBS Lett 424: 41-45, 1998.
30. Griffith TS, Fialkov JM, Scott DL, Azuhata T, Williams RD, Wall NR, Altieri DC and Sandler AD: Induction and regulation of tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand-mediated apoptosis in renal cell carcinoma. Cancer Res 62: 3093-3099, 2002.
31. Kim SH, Kim K, Kwagh JG, Dicker DT, Herlyn M, Rustgi AK, Chen Y and El-Deiry WS: Death induction by recombinant native TRAIL and its prevention by a caspase-9 inhibitor in primary human esophageal epithelial cells. J Biol Chem 279: 40044-40052, 2004.
32. Nagane M, Huang HJ and Cavenee WK: The potential of TRAIL for cancer chemotherapy. Apoptosis 6: 191-197, 2001.
33. Yeow WS, Baras A, Chua A, Nguyen DM, Sehgal SS, Schrump DS and Nguyen DM: Gossypol, a phytochemical with BH3-mimetic property, sensitizes cultured thoracic cancer cells to Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand. J Thorac Cardiovasc Surg 132: 1356-1362, 2006.
34. Naka T, Sugamura K, Hylander BL, Widmer MB, Rustum YM and Repasky EA: Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with chemotherapeutic agents on patients' colon tumors grown in SCID mice. Cancer Res 62: 5800-5806, 2002.
35. Van Geelen CM, De Vries EG and De Jong S: Lessons from TRAIL-resistance mechanisms in colorectal cancer cells: paving the road to patient-tailored therapy. Drug Resist Updat 7: 345-358, 2004.
36. Tsai WS, Yeow WS, Chua A, Reddy RM, Nguyen DM, Schrump DS and Nguyen DM: Enhancement of Apo2L/TRAIL-mediated cytotoxicity in esophageal cancer cells by cisplatin. Mol Cancer Ther 5: 2977-2990, 2006.
37. Kondo K, Yamasaki S, Inoue N, Sugie T, Teratani N, Kan T and Shimada Y: Prospective antitumor effects of the combination of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and cisplatin against esophageal squamous cell carcinoma. Surg Today 36: 966-974, 2006.
38. Teraishi F, Kagawa S, Watanabe T, Tango Y, Kawashima T, Umeoka T, Nisizaki M, Tanaka N and Fujiwara T: ZD1839 (Gefitinib, 'Iressa'), an epidermal growth factor receptor-tyrosine kinase inhibitor, enhances the anti-cancer effects of TRAIL in human esophageal squamous cell carcinoma. FEBS Lett 579: 4069-4075, 2005.
39. Nagane M, Pan G, Weddle JJ, Dixit VM, Cavenee WK and Huang HJ: Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo. Cancer Res 60: 847-853, 2000.
40. Schuller-Levis GB and Park E: Taurine: new implications for an old amino acid. FEMS Microbiol Lett 226: 195-202, 2003.
41. Baker DM, Jones JA, Nguyen-Van-Tam JS, Lloyd JH, Morris DL, Bourke JB, Steele RJ and Hardcastle JD: Taurolidine peritoneal lavage as prophylaxis against infection after elective colorectal surgery. Br J Surg 81: 1054-1056, 1994.
42. McCartney AC and Browne MK: Clinical studies on administration of taurolin in severe sepsis: a preliminary study. Prog Clin Biol Res 272: 361-371, 1988.
43. Willatts SM, Radford S and Leitermann M: Effect of the antiendotoxic agent, taurolidine, in the treatment of sepsis syndrome: a placebo-controlled, double-blind trial. Crit Care Med 23: 1033-1039, 1995.
44. Braumann C, Henke W, Jacobi CA and Dubiel W: The tumorsuppressive reagent taurolidine is an inhibitor of protein biosynthesis. Int J Cancer 112: 225-230, 2004.
45. Calabresi P, Goulette FA and Darnowski JW: Taurolidine: cytotoxic and mechanistic evaluation of a novel antineoplastic agent. Cancer Res 61: 6816-6821, 2001.
46. Darnowski JW, Goulette FA, Cousens LP, Chatterjee D and Calabresi P: Mechanistic and antineoplastic evaluation of taurolidine in the DU145 model of human prostate cancer. Cancer Chemother Pharmacol 54: 249-258, 2004.
47. McCourt M, Wang JH, Sookhai S and Redmond HP: Taurolidine inhibits tumor cell growth in vitro and in vivo. Ann Surg Oncol 7: 685-691, 2000.
48. Nici L, Monfils B and Calabresi P: The effects of taurolidine, a novel antineoplastic agent, on human malignant mesothelioma. Clin Cancer Res 10: 7655-7661, 2004.
49. Ribizzi I, Darnowski JW, Goulette FA, Akhtar MS, Chatterjee D and Calabresi P: Taurolidine: preclinical evaluation of a novel, highly selective, agent for bone marrow purging. Bone Marrow Transplant 29: 313-319, 2002.
50. Shrayer DP, Lukoff H, King T and Calabresi P: The effect of Taurolidine on adherent and floating subpopulations of melanoma cells. Anticancer Drugs 14: 295-303, 2003.
51. Opitz I, Sigrist B, Hillinger S, Lardinois D, Stahel R, Weder W and Hopkins-Donaldson S: Taurolidine and povidone-iodine induce different types of cell death in malignant pleural mesothelioma. Lung Cancer 56: 327-336, 2007.
52. Walters DK, Muff R, Langsam B, Gruber P, Born W and Fuchs B: Taurolidine: a novel anti-neoplastic agent induces apoptosis of osteosarcoma cell lines. Invest New Drugs 25: 305-312, 2007.
53. Braumann C, Winkler G, Rogalla P, Menenakos C and Jacobi CA: Prevention of disease progression in a patient with a gastric cancer-re-recurrence. Outcome after intravenous treatment with the novel antineoplastic agent taurolidine. Report of a case. World J Surg Oncol 4: 34, 2006.
54. Stendel R, Scheurer L, Schlatterer K, Stalder U, Pfirrmann RW, Fiss I, Mohler H and Bigler L: Pharmacokinetics of taurolidine following repeated intravenous infusions measured by HPLC-ESI-MS/MS of the derivatives taurultame and taurinamide in glioblastoma patients. Clin Pharmacokinet 46: 513-524, 2007.
55. Stendel R, Picht T, Schilling A, Heidenreich J, Loddenkemper C, Janisch W and Brock M: Treatment of glioblastoma with intravenous taurolidine. First clinical experience. Anticancer Res 24: 1143-1147, 2004.
56. Han Z, Ribbizi I, Pantazis P, Wyche J, Darnowski J and Calabresi P: The antibacterial drug taurolidine induces apoptosis by a mitochondrial cytochrome c-dependent mechanism. Anticancer Res 22: 1959-1964, 2002.
57. Rodak R, Kubota H, Ishihara H, Eugster HP, Konu D, Mohler H, Yonekawa Y and Frei K: Induction of reactive oxygen intermediates-dependent programmed cell death in human malignant ex vivo glioma cells and inhibition of the vascular endothelial growth factor production by taurolidine. J Neurosurg 102: 1055-1068, 2005.
58. Jacobi CA, Menenakos C and Braumann C: Taurolidine - a new drug with anti-tumor and anti-angiogenic effects. Anticancer Drugs 16: 917-921, 2005.
59. Stendel R, Scheurer L, Stoltenburg-Didinger G, Brock M and Mohler H: Enhancement of Fas-ligand-mediated programmed cell death by taurolidine. Anticancer Res 23: 2309-2314, 2003.
60. D'Osualdo A, Ferlito F, Prigione I, et al: Neutrophils from patients with TNFRSF1A mutations display resistance to tumor necrosis factor-induced apoptosis: pathogenetic and clinical implications. Arthritis Rheum 54: 998-1008, 2006.
61. Weingartner M, Siegmund D, Schlecht U, Fotin-Mleczek M, Scheurich P and Wajant H: Endogenous membrane tumor necrosis factor (TNF) is a potent amplifier of TNF receptor 1-mediated apoptosis. J Biol Chem 277: 34853-34859, 2002.
62. Hu WH, Mo XM, Walters WM, Brambilla R and Bethea JR: TNAP, a novel repressor of NF-kappaB-inducing kinase, suppresses NF-kappaB activation. J Biol Chem 279: 35975-35983, 2004.
63. Soni V, Cahir-McFarland E and Kieff E: LMP1 TRAfficking activates growth and survival pathways. Adv Exp Med Biol 597: 173-187, 2007.
64. Kasof GM, Lu JJ, Liu D, Speer B, Mongan KN, Gomes BC and Lorenzi MV: Tumor necrosis factor-alpha induces the expression of DR6, a member of the TNF receptor family, through activation of NF-kappaB. Oncogene 20: 7965-7975, 2001.
65. Mikami T, Koyama T, Koyama T, Imakiire A, Yamamoto K, Furuhata M, Toyota H and Mizuguchi J: C-jun N-terminal kinase activation is required for apoptotic cell death induced by TNF-related apoptosis-inducing ligand plus DNA-damaging agents in sarcoma cell lines. Anticancer Res 26: 1153-1160, 2006.
66. Paner GP, Silberman S, Hartman G, Micetich KC, Aranha GV and Alkan S: Analysis of signal transducer and activator of transcription 3 (STAT3) in gastrointestinal stromal tumors. Anticancer Res 23: 2253-2260, 2003.
67. Kusaba M, Nakao K, Goto T, et al: Abrogation of constitutive STAT3 activity sensitizes human hepatoma cells to TRAIL-mediated apoptosis. J Hepatol (In press).
68. Li P, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmad M, Alnemri ES and Wang X: Cytochrome cand dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 91: 479-489, 1997.
69. Park SM, Schickel R and Peter ME: Non-apoptotic functions of FADD-binding death receptors and their signaling molecules. Curr Opin Cell Biol 17: 610-616, 2005.
70. Papa S, Zazzeroni F, Bubici C, et al: Gadd45 beta mediates the NF-kappa B suppression of JNK signalling by targeting MKK7/JNKK2. Nat Cell Biol 6: 146-153, 2004.
71. Lauricella M, Emanuele S, D'Anneo A, Calvaruso G, Vassallo B, Carlisi D, Portanova P, Vento R and Tesoriere G: JNK and AP-1 mediate apoptosis induced by bortezomib in HepG2 cells via FasL/caspase-8 and mitochondria-dependent pathways. Apoptosis 11: 607-625, 2006.
72. Jin Z and El-Deiry WS: Distinct signaling pathways in TRAIL-versus tumor necrosis factor-induced apoptosis. Mol Cell Biol 26: 8136-8148, 2006.
73. Karin M and Chang L: AP-l-glucocorticoid receptor crosstalk taken to a higher level. J Endocrinol 169: 447-451, 2001.
74. Park SY, Billiar TR and Seol DW: IFN-gamma inhibition of TRAIL-induced IAP-2 upregulation, a possible mechanism of IFN-gamma-enhanced TRAIL-induced apoptosis. Biochem Biophys Res Commun 291: 233-236, 2002.
75. Piva R, Gianferretti P, Ciucci A, Taulli R, Belardo G and Santoro MG: 15-Deoxy-delta 12,14-prostaglandin J2 induces apoptosis in human malignant B cells: an effect associated with inhibition of NF-kappa B activity and down-regulation of anti-apoptotic proteins. Blood 105: 1750-1758, 2005.
76. Jaattela M, Mouritzen H, Elling F and Bastholm L: A20 zinc finger protein inhibits TNF and IL-1 signaling. J Immunol 156: 1166-1173, 1996.
77. Wallach D, Varfolomeev EE, Malinin NL, Goltsev YV, Kovalenko AV and Boldin MP: Tumor necrosis factor receptor and Fas signaling mechanisms. Annu Rev Immunol 17: 331-367, 1999.
78. Newton K, Kurts C, Harris AW and Strasser A: Effects of a dominant interfering mutant of FADD on signal transduction in activated T cells. Curr Biol 11: 273-276, 2001.
79. Walsh CM, Wen BG, Chinnaiyan AM, O'Rourke K, Dixit VM and Hedrick SM: A role for FADD in T cell activation and development. Immunity 8: 439-449, 1998.
80. Zornig M, Hueber AO and Evan G: p53-dependent impairment of T-cell proliferation in FADD dominant-negative transgenic mice. Curr Biol 8: 467-470, 1998.
81. Kumar-Sinha C, Varambally S, Sreekumar A and Chinnaiyan AM: Molecular cross-talk between the TRAIL and interferon signaling pathways. J Biol Chem 277: 575-585, 2002.
82. Monson JR, Ramsey PS and Donohue JH: Taurolidine inhibits tumour necrosis factor (TNF) toxicity - new evidence of TNF and endotoxin synergy. Eur J Surg Oncol 19: 226-231, 1993.
83. Marcinkiewicz J, Kurnyta M, Biedron R, Bobek M, Kontny E and Maslinski W: Anti-inflammatory effects of taurine derivatives (taurine chloramine, taurine bromamine and taurolidine) are mediated by different mechanisms. Adv Exp Med Biol 583: 481-492, 2006.
84. Lin MT, Chang CC, Chen ST, Chang HL, Su JL, Chau YP and Kuo ML: Cyr61 expression confers resistance to apoptosis in breast cancer MCF-7 cells by a mechanism of NF-kappaB-dependent XIAP up-regulation. J Biol Chem 279: 24015-24023, 2004.
85. Shukla S and Gupta S: Suppression of constitutive and tumor necrosis factor alpha-induced nuclear factor (NF)-kappaB activation and induction of apoptosis by apigenin in human prostate carcinoma PC-3 cells: correlation with down-regulation of NF-kappaB-responsive genes. Clin Cancer Res 10: 3169-3178, 2004.
86. Pham LV, Tamayo AT, Yoshimura LC, Lo P and Ford RJ: Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis. J Immunol 171: 88-95, 2003.
87. Brecht S, Kirchhof R, Chromik A, et al: Specific pathophysiological functions of JNK isoforms in the brain. Eur J Neurosci 21: 363-377, 2005.
88. Das A, Banik NL and Ray SK: Mechanism of apoptosis with the involvement of calpain and caspase cascades in human malignant neuroblastoma SH-SY5Y cells exposed to flavonoids. Int J Cancer 119: 2575-2585, 2006.
89. Shankar S and Srivastava RK: Enhancement of therapeutic potential of TRAIL by cancer chemotherapy and irradiation: mechanisms and clinical implications. Drug Resist Updat 7: 139-156, 2004.